Dossier assessment

Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-155
Last updated

Report documents

  1. Extract of dossier assessment

    Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 343 kB, EN, not accessible
  2. Dossier assessment

    Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 551 kB, DE, not accessible

Dossier assessment

Indication:

Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to either conventional treatment or a biologic drug

Result of dossier assessment:
  • adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or have intolerance or contraindications to conventional treatment: added benefit not proven
  • Adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or are intolerant to treatment with a biologic drug (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven

Project details

Project no.
A21-155
Commission
Commission awarded on 01.12.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 2.0 of the dossier assessment replaces version 1.0 published on 2022-03-01.

Connected Projects

  1. Dossier assessment

    Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-90
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form